Skip to main content
Menu closed
  • Patients and Caregivers Home
    • Is BAQSIMI for me?
    • What is BAQSIMI?
    • When to use BAQSIMI?
    • How to use BAQSIMI?
    • BAQSIMI basics
  • House For Healthcare Providers
    • Pediatric Patients Home
      • Efficacy
      • Safety
      • Administration/Usage
      • MOA
    • Adult Patients Home
      • Efficacy
      • Safety
      • Administration/Usage
      • MOA
    • BAQSIMI Product Monograph
    • Severe Hypoglycemia Information
  • Got Your BAQ™ Resources
Globe Loading... Reveal available languages

BAQSIMI demonstrated comparable efficacy to injectable glucagon in adult patients with Type 1 diabetes

Treatment success for BAQSIMI and glucagon injectable*

X-AXIS: % Treatment Success
LEGEND: blue square BAQSIMI (3 mg)
grey square injectable glucagon (1 mg)
98.7%  
100%  
Efficacy Graph

Treatment success was defined as the percentage of patients with either an increase in blood glucose to ≥3.9 mmol/L or an increase of ≥1.1 mmol/L from blood glucose nadir within 30 minutes.

Nadir is defined as minimum glucose measurement at the time of or within 10 minutes after glucagon administration. The mean nadir blood glucose was 2.5 mmol/L for BAQSIMI and 2.7 mmol/L for injectable glucagon.

* Study IGBC was a randomized, multicenter, open-label, 2-period, crossover study in adult patients with Type 1 diabetes (n=77) that compared the efficacy of a single 3 mg dose of BAQSIMI versus 1 mg injectable glucagon for treatment of hypoglycemia induced by intravenous insulin with a target blood glucose of <2.8 mmol/L. The primary efficacy measure was the proportion of patients achieving treatment success.

BAQSIMI began raising mean plasma glucose as early as 5 minutes*

Mean plasma glucose concentrations over time with BAQSIMI


X-AXIS: Time (minutes)
Y-AXIS: Mean glucose (mmol/L)
LEGEND: blue circle BAQSIMI 3 mg (n=66)
grey circle Injectable glucagon 1 mg (n=66)
Efficacy Graph

* A randomized, multicenter, crossover noninferiority trial was conducted in adult patients with Type 1 diabetes. Hypoglycemia was induced with intravenous insulin and treated by 3 mg intranasal glucagon or 1 mg intra-muscular glucagon. Plasma glucose was measured after each treatment was given.

ICON NOSE

Nasal congestion does not impact the absorption of BAQSIMI

Download the full study publication

Download now
« Adult Patients Home
Safety »

Clinical use:
BAQSIMI has not been studied in pediatric patients less than 4 years old.

Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.



Contraindications:

  • Hypersensitivity to glucagon or to any ingredient in the formulation or container
  • Pheochromocytoma
  • Insulinoma



Most serious warnings and precautions:
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as IV access can be established.

States of starvation, adrenal insufficiency or chronic hypoglycemia: Because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.



Other relevant warnings and precautions:

  • Cardiovascular effects
  • Driving and operating machinery
  • Pheochromocytoma
  • Insulinoma
  • Sensitivity and resistance to glucagon
  • Pregnant women
  • Breast-feeding
  • Pediatrics (<4 years of age)
  • Geriatrics (≥65 years of age)
  • Use in patients with Type 2 diabetes taking sulfonylureas
  • Use with alcohol
  • Monitoring and laboratory tests



For more information:
Consult the Product Monograph at http://pi.lilly.com/ca/baqsimi-ca-pm.pdf for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-888-545-5972.

  • Privacy
  • Terms of Use
  • Disclaimer
  • Accessibility
  • Site map
 

BAQSIMI™ is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates.



PP-GN-CA-0018 © Eli Lilly Canada Inc. 2021

Privacy Terms of Use Disclaimer Accessibility Site map
Lilly